Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07628972 · ClinicalTrials.gov registry record · Phase 1
Quercetin Dyskeratosis Congenita (DC)/Telomere Biology Disorders (TBD)
A Phase 1 study, sponsored by Children's Hospital Medical Center, Cincinnati.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT07628972 is a Phase 1 study that is actively recruiting participants, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 12 participants.
The verdict
NCT07628972, a Phase 1 study, is actively recruiting participants, sponsored by Children's Hospital Medical Center, Cincinnati.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to see if a vitamin-like substance called quercetin is safe for people who have a rare condition called Dyskeratosis congenita (DC) or telomere biology disorders (TBD).
Interventions
- DRUG Quercetin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-05-29 |
| Est. Completion | 2028-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07628972
The ClinicalTrials.gov registry entry for NCT07628972 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Quercetin is the first listed.
NCT07628972 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07628972 about?
NCT07628972 is a clinical study titled "Quercetin Dyskeratosis Congenita (DC)/Telomere Biology Disorders (TBD)". The purpose of this study is to see if a vitamin-like substance called quercetin is safe for people who have a rare condition called Dyskeratosis congenita (DC) or telomere biology disorders (TBD).
What is the current status of trial NCT07628972?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2026-05-29. Estimated completion is 2028-09.
What interventions are being tested in trial NCT07628972?
The interventions under investigation include: Quercetin (DRUG).
Who is sponsoring clinical trial NCT07628972?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.